MedTrace Logo

Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma

NCT03413436 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 733

Last updated 2020-08-28

No results posted yet for this study

Summary

The multicenter real-world and propensity score matching comparative study was designed to explore the toxicity and effectiveness of Lobaplation or Cisplatin based adjuvant chemotherapy in esophageal carcinoma

Conditions

  • Esophageal Cancer

Interventions

DRUG

Lobaplatin

at least one cycle adjuvant chemotherapy after esophagectomy

DRUG

Cisplatin

at least one cycle adjuvant chemotherapy after esophagectomy

Sponsors & Collaborators

  • Henan Cancer Hospital

    lead OTHER_GOV

Principal Investigators

  • Yin Li, Dr. · The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2018-02-21
Completion
2018-02-21

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413436 on ClinicalTrials.gov